Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 11/20 | 0.51 |
| ▸ | RXRB | P28702 | 10/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.51 |
| ▸ | RXRG | P48443 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13244605 | 0.88 | RXRA (0.42) | RXRARXRBNR4A2RXRGALDH1A1 | |
| SCHEMBL14648434 | 0.87 | KMT2A (0.48) | ALDH1A1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL17088961 | 0.85 | RXRA (0.37) | RXRARXRBNR4A2RXRGALDH1A1 | |
| SCHEMBL19895091 | 0.84 | SMN1; SMN2 (0.48) | RXRARXRBNR4A2ALDH1A1NPC1 | |
| SCHEMBL12117875 | 0.84 | RXRA (0.36) | RXRARXRBNR4A2RXRGALDH1A1 | |
| SCHEMBL1313112 | 0.84 | LOXL2 (0.51) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL4741957 | 0.84 | ALDH1A1 (0.44) | RXRARXRBNR4A2RXRGALDH1A1 | |
| SCHEMBL5029906 | 0.83 | CA2 (0.48) | RXRARXRBRXRGALDH1A1POLB | |
| SCHEMBL17440156 | 0.83 | ALDH1A1 (0.45) | RXRARXRBNR4A2RXRGALDH1A1 | |
| SCHEMBL992588 | 0.83 | MLYCD (0.43) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124311-A1 | POLYMER-DRUG CONJUGATES FOR STING PATHWAY ACTIVATION | UNIV VANDERBILT (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2024149093-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND CONJUGATE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-07-18 | — | — | WO | disclosed |
| US-20240226107-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240226107-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240226107-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| EP-4321515-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | Simcere Zaiming Pharmaceutical Co., Ltd. (CN) | 2024-02-14 | — | — | EP | disclosed |
| US-20230398228-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MAN CO LTD (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230398228-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MAN CO LTD (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230398228-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MAN CO LTD (JP) | 2023-12-14 | — | — | US | disclosed |
| CN-117136189-A | Ubiquitin-specific protease 1 (USP 1) inhibitors | 先声再明医药有限公司 | 2023-11-28 | — | — | CN | disclosed |
| WO-2010133544-A1 | PIPERAZINE AND AMINOPYRROLIDINE COMPOUNDS AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2010-11-25 | — | — | WO | disclosed |
| US-20090227617-A1 | Esters Of Glucuronide Prodrugs Of Anthracyclines And Method Of Preparation And Use In Tumor-Selective Chemotherapy | PHARMACHEMIE B.V. (NL) | 2009-09-10 | — | — | US | disclosed |
| US-6828392-B2 | For use as solid supports for organic synthesis, for enzymatic assays, for immobilization of biomolecules, for controlled release of drugs, and for chromatographic separations | CARLSBERG A/S (DK) | 2004-12-07 | — | — | US | disclosed |
| EP-0751144-B1 | Novel anthracycline prodrugs, method for preparation as well as their use in selective chemotherapy | PHARMACHEMIE BV (NL) | 2004-10-06 | — | — | EP | disclosed |
| US-20030096918-A1 | Hydroxy and amine functionalised resins | CARLSBERG A/S (DK) | 2003-05-22 | — | — | US | disclosed |
| US-5710135-A | ENZYMATICALLY CLEAVABLE; ANTITUMOR AGENTS | PHARMACHEMIE B.V. (NL) | 1998-01-20 | — | — | US | disclosed |
| EP-0751144-A1 | Novel anthracycline prodrugs, method for preparation as well as their use in selective chemotherapy | PHARMACHEMIE B.V. (NL) | 1997-01-02 | — | — | EP | disclosed |
| EP-0236880-B1 | Penem derivatives | ERBA CARLO SPA (IT) | 1994-07-20 | — | — | EP | disclosed |
| US-4886793-A | PENICILLINS; HUMANS OR ANIMALS | FARMITALIA CARLO ERBA, S.R.L. (IT) | 1989-12-12 | — | — | US | disclosed |
| EP-0236880-A2 | Penem derivatives | FARMITALIA CARLO ERBA S.r.l. (IT) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226107-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | USP1, USP2, USP3 | RXRA 3910/4885RXRB 3708/4885NR4A2 3394/4885 |
| US-20260124311-A1 | POLYMER-DRUG CONJUGATES FOR STING PATHWAY ACTIVATION | STING1, TLR9, TLR3 | RXRA 3251/4885RXRB 2973/4885NR4A2 3218/4885 |
| US-20090227617-A1 | Esters Of Glucuronide Prodrugs Of Anthracyclines And Method Of Preparation And Use In Tumor-Selective Chemotherapy | GALE, UGGT1, UGT1A3 | RXRA 2511/4885RXRB 2502/4885NR4A2 2279/4885 |
| US-20230398228-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | FOLR1, FOLR2, TUBB1 | RXRA 2895/4885RXRB 1775/4885NR4A2 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.